{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T07:22:30Z","timestamp":1794640950857,"version":"4.9.1"},"reference-count":33,"publisher":"SAGE Publications","issue":"4","license":[{"start":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T00:00:00Z","timestamp":1776384000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T00:00:00Z","timestamp":1776384000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"DOI":"10.13039\/501100005155","name":"Azrieli Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005155","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014405","name":"Centre for Addiction and Mental Health Foundation","doi-asserted-by":"publisher","award":["Discovery Fund and womenmind\u2122"],"award-info":[{"award-number":["Discovery Fund and womenmind\u2122"]}],"id":[{"id":"10.13039\/100014405","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000196","name":"Canada Foundation for Innovation","doi-asserted-by":"publisher","award":["JELF"],"award-info":[{"award-number":["JELF"]}],"id":[{"id":"10.13039\/501100000196","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001804","name":"Canada Research Chairs","doi-asserted-by":"publisher","award":["Tier 1"],"award-info":[{"award-number":["Tier 1"]}],"id":[{"id":"10.13039\/501100001804","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000864","name":"Michael J. Fox Foundation for Parkinson's Research","doi-asserted-by":"publisher","award":["MJFF-024348"],"award-info":[{"award-number":["MJFF-024348"]}],"id":[{"id":"10.13039\/100000864","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000065","name":"National Institute of Neurological Disorders and Stroke","doi-asserted-by":"publisher","award":["U19 NS110456"],"award-info":[{"award-number":["U19 NS110456"]}],"id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012171","name":"Ontario Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012171","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Journal of Parkinson\u2019s Disease"],"published-print":{"date-parts":[[2026,6]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      Parkinson's disease (PD) and multiple system atrophy (MSA) are considered \u03b1-synucleinopathies, characterized by the presence of pathological \u03b1-synuclein (\u03b1-syn) aggregates. A positron emission tomography (PET) tracer for imaging \u03b1-syn aggregates\n                      <jats:italic toggle=\"yes\">in vivo<\/jats:italic>\n                      is highly sought after, as disease progression correlates with the accumulation of aggregated \u03b1-syn. We recently reported [\n                      <jats:sup>18<\/jats:sup>\n                      F]asyn-44 as a radiotracer for \u03b1-syn, worthy of evaluation in higher species, based on\n                      <jats:italic toggle=\"yes\">in vitro<\/jats:italic>\n                      binding data from human brain tissues and\n                      <jats:italic toggle=\"yes\">in vivo<\/jats:italic>\n                      PET imaging studies in rodents.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>\n                      [\n                      <jats:sup>3<\/jats:sup>\n                      H]ACI-12589 is a promising \u03b1-syn PET tracer which recently showed binding in MSA patients but appears to have limited utility in other \u03b1-synucleinopathies. Objective 1) compare the\n                      <jats:italic toggle=\"yes\">in vitro<\/jats:italic>\n                      binding properties of our lead, [\n                      <jats:sup>3<\/jats:sup>\n                      H]asyn-44, to [\n                      <jats:sup>3<\/jats:sup>\n                      H]ACI-12589; Objective 2) evaluate [\n                      <jats:sup>18<\/jats:sup>\n                      F]asyn-44 and [\n                      <jats:sup>18<\/jats:sup>\n                      F]ACI-12589 kinetics by\n                      <jats:italic toggle=\"yes\">in vivo<\/jats:italic>\n                      PET imaging in normal rodents; Objective 3) assess pharmacokinetic properties and metabolism of [\n                      <jats:sup>18<\/jats:sup>\n                      F]asyn-44 in normal pig and non-human primate (NHP).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      <jats:italic toggle=\"yes\">In vitro<\/jats:italic>\n                      autoradiography with [\n                      <jats:sup>3<\/jats:sup>\n                      H]asyn-44 and [\n                      <jats:sup>3<\/jats:sup>\n                      H]ACI-12589 was performed to compare radiotracer binding in PD, MSA, Alzheimer's disease and healthy control post-mortem brain tissue. Additionally, preclinical PET imaging was performed in rats with [\n                      <jats:sup>18<\/jats:sup>\n                      F]ACI-12589 to compare with our previously reported [\n                      <jats:sup>18<\/jats:sup>\n                      F]asyn-44 data. Further evaluation of [\n                      <jats:sup>18<\/jats:sup>\n                      F]asyn-44 in higher species was carried out by preclinical PET imaging in pig and NHP with metabolite analysis. Liver microsome assays and mass spectrometry were performed to identify the metabolites formed in NHP.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      [\n                      <jats:sup>3<\/jats:sup>\n                      H]Asyn-44 and [\n                      <jats:sup>3<\/jats:sup>\n                      H]ACI-12589 displayed different binding properties in both PD and MSA tissue, suggesting that the tracers target different binding sites and asyn-44 might therefore be more suited for PD imaging. In the pig, [\n                      <jats:sup>18<\/jats:sup>\n                      F]asyn-44 readily entered the brain and no brain penetrant metabolites were observed in arterial blood samples. In the NHP, [\n                      <jats:sup>18<\/jats:sup>\n                      F]asyn-44 readily entered the brain but was rapidly metabolized. Radiolabeled metabolites of asyn-44 were proposed and will be considered in the design of future derivatives.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>\n                      Species differences in metabolism of [\n                      <jats:sup>18<\/jats:sup>\n                      F]asyn-44 are observed between pig and NHP, and do not support the further translation of [\n                      <jats:sup>18<\/jats:sup>\n                      F]asyn-44. Additionally, autoradiography with [\n                      <jats:sup>3<\/jats:sup>\n                      H]asyn-44 revealed low signal specificity and high non-displaceable binding. We report evidence for off-target binding of [\n                      <jats:sup>3<\/jats:sup>\n                      H]ACI-12589 to amyloid-\u03b2 plaques. The limitations of both [\n                      <jats:sup>3<\/jats:sup>\n                      H]asyn-44 and [\n                      <jats:sup>3<\/jats:sup>\n                      H]ACI-12589 reported here support the development of additional derivatives and structural scaffolds of asyn-44 with the potential to improve radiotracer specificity and selectivity towards \u03b1-syn.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/1877718x261431108","type":"journal-article","created":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T13:48:32Z","timestamp":1776433712000},"page":"683-698","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["Autoradiography and preclinical PET studies with radiolabeled asyn-44 and ACI-12589 for imaging \u03b1-synuclein"],"prefix":"10.1177","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1217-764X","authenticated-orcid":false,"given":"Cassis","family":"Varlow","sequence":"first","affiliation":[{"name":"Neurobiology Research Unit, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8207-3358","authenticated-orcid":false,"given":"Anna","family":"Pees","sequence":"additional","affiliation":[{"name":"Azrieli Centre for Neuro-Radiochemistry, Brain Health Imaging Centre, Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health (CAMH), Toronto, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey S","family":"Stehouwer","sequence":"additional","affiliation":[{"name":"Department of Radiology, University of Pittsburgh, Pittsburgh, PA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann-Kathrin","family":"Grotegerd","sequence":"additional","affiliation":[{"name":"Werner Siemens Imaging Center, Department of Preclinical Imaging and Radiopharmacy, University of Tuebingen, Tuebingen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2216-2524","authenticated-orcid":false,"given":"Daniel","family":"Bleher","sequence":"additional","affiliation":[{"name":"Werner Siemens Imaging Center, Department of Preclinical Imaging and Radiopharmacy, University of Tuebingen, Tuebingen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dinahlee Saturnino","family":"Guarino","sequence":"additional","affiliation":[{"name":"Department of Radiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anton","family":"Lindberg","sequence":"additional","affiliation":[{"name":"Azrieli Centre for Neuro-Radiochemistry, Brain Health Imaging Centre, Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health (CAMH), Toronto, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junchao","family":"Tong","sequence":"additional","affiliation":[{"name":"Azrieli Centre for Neuro-Radiochemistry, Brain Health Imaging Centre, Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health (CAMH), Toronto, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian J","family":"Lopresti","sequence":"additional","affiliation":[{"name":"Department of Radiology, University of Pittsburgh, Pittsburgh, PA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashley C","family":"Knight","sequence":"additional","affiliation":[{"name":"Preclinical and Translational Sciences - Imaging, Takeda Pharmaceutical Company, Cambridge, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Merlin","family":"Zabrocki","sequence":"additional","affiliation":[{"name":"Department of Drug Design and Pharmacology, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arafat","family":"Nasser","sequence":"additional","affiliation":[{"name":"Neurobiology Research Unit, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8956-1207","authenticated-orcid":false,"given":"Vladimir","family":"Shalgunov","sequence":"additional","affiliation":[{"name":"Department of Clinical Physiology, Nuclear Medicine &amp; PET, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-0360-8538","authenticated-orcid":false,"given":"Elena","family":"Ferri","sequence":"additional","affiliation":[{"name":"Health Innovative Products and Technologies (HIP-TECH) PhD Program, Department of Life Sciences, University of Modena and Reggio Emilia, Modena, Italy"},{"name":"Department of Life Sciences, University of Modena and Reggio Emilia, Modena, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Cannazza","sequence":"additional","affiliation":[{"name":"Department of Life Sciences, University of Modena and Reggio Emilia, Modena, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"McQuade","sequence":"additional","affiliation":[{"name":"Preclinical and Translational Sciences - Imaging, Takeda Pharmaceutical Company, Cambridge, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9811-0950","authenticated-orcid":false,"given":"Chester A","family":"Mathis","sequence":"additional","affiliation":[{"name":"Department of Radiology, University of Pittsburgh, Pittsburgh, PA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert H","family":"Mach","sequence":"additional","affiliation":[{"name":"Department of Radiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Umberto M","family":"Battisti","sequence":"additional","affiliation":[{"name":"Department of Drug Design and Pharmacology, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristina","family":"Herfert","sequence":"additional","affiliation":[{"name":"Werner Siemens Imaging Center, Department of Preclinical Imaging and Radiopharmacy, University of Tuebingen, Tuebingen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias M","family":"Herth","sequence":"additional","affiliation":[{"name":"Department of Drug Design and Pharmacology, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gitte M","family":"Knudsen","sequence":"additional","affiliation":[{"name":"Neurobiology Research Unit, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark"},{"name":"Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil","family":"Vasdev","sequence":"additional","affiliation":[{"name":"Azrieli Centre for Neuro-Radiochemistry, Brain Health Imaging Centre, Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health (CAMH), Toronto, ON, Canada"},{"name":"Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2026,4,17]]},"reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.1002\/cmdc.201900689"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.neulet.2019.134316"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.semnuclmed.2017.06.003"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.3390\/ph14090847"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40336-016-0217-4"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-022-11267-9"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41531-024-00672-8"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuint.2022.105422"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.nucmedbio.2022.04.001"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1002\/mds.21065"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0197-4580(02)00065-9"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.4172\/2161-0460.1000444"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.122.263918"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2023.06.004"},{"issue":"834","key":"e_1_3_3_16_2","first-page":"1","article-title":"a-synuclein PET imaging: from clinical utility in multiple system atrophy to the possible diagnosis of Parkinson\u2019s disease","volume":"14","author":"Capotosti F","year":"2025","unstructured":"Capotosti F. a-synuclein PET imaging: from clinical utility in multiple system atrophy to the possible diagnosis of Parkinson\u2019s disease. Cells 2025; 14(834): 1\u20139. doi:https:\/\/doi.org\/10.3390\/cells14110834","journal-title":"Cells"},{"issue":"1108","key":"e_1_3_3_17_2","first-page":"1","article-title":"Discovery of N-(6-Methoxypyridin-3-yl)quinoline-2-amine derivatives for imaging aggregated \u03b1-Synuclein in Parkinson\u2019s disease with positron emission tomography","volume":"14","author":"Zhao H","year":"2025","unstructured":"Zhao H, Huang T, Dhavale DD, et al. Discovery of N-(6-Methoxypyridin-3-yl)quinoline-2-amine derivatives for imaging aggregated \u03b1-Synuclein in Parkinson\u2019s disease with positron emission tomography. Cells 2025; 14(1108): 1\u201323. doi:https:\/\/doi.org\/10.3390\/cells14141108","journal-title":"Cells"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-42305-3"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuron.2024.05.006"},{"key":"e_1_3_3_20_2","article-title":"[11C] MODAG 005\u2013a novel PET tracer targeting alpha-synuclein aggregates in the brain","volume":"2","author":"Saw RS","year":"2025","unstructured":"Saw RS, Buss S, Schmidt F, et al. [11C] MODAG 005\u2013a novel PET tracer targeting alpha-synuclein aggregates in the brain. Preprint 2025; Version 2. doi:https:\/\/doi.org\/10.21203\/rs.3.rs-2189800\/v2","journal-title":"Preprint"},{"key":"e_1_3_3_21_2","first-page":"1","article-title":"Alpha-synuclein binders and methods of use","author":"Bennacef I","year":"2024","unstructured":"Bennacef I, Fawaz MV, Hostetler ED, et al. Alpha-synuclein binders and methods of use. World Intellectual Property Organization 2024: 1\u2013188. WO 2024\/186584 A2.","journal-title":"World Intellectual Property Organization"},{"key":"e_1_3_3_22_2","unstructured":"Wang C. PET Imaging Evaluation of [11C]SY08. ClinicalTrials.gov identifier: NCT06098612 Updated March 12 2024 Accessed September 9 2025. https:\/\/clinicaltrials.gov\/study\/NCT06098612."},{"key":"e_1_3_3_23_2","article-title":"Clinical Study of [18F]-FD4 PET Imaging of \u03b1-Synuclein in the Brain of Patients with Parkinsonian Disorder","author":"Ge JGY","year":"2024","unstructured":"Ge JGY. Clinical Study of [18F]-FD4 PET Imaging of \u03b1-Synuclein in the Brain of Patients with Parkinsonian Disorder. Chinese Clinical Trial Registry 2024. ChiCTR2400093128.","journal-title":"Chinese Clinical Trial Registry"},{"key":"e_1_3_3_24_2","first-page":"1","article-title":"PET imaging of alpha-synuclein from radiotracer design through in vitro and in vivo translation","author":"Pees A","year":"2026","unstructured":"Pees A, Grotegerd A-K, Bleher D, et al. PET imaging of alpha-synuclein from radiotracer design through in vitro and in vivo translation. Eur J Nucl Med Mol Imaging 2026; Epub ahead of print: 1\u201329. doi:https:\/\/doi.org\/10.1007\/s00259-025-07695-0","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"e_1_3_3_25_2","doi-asserted-by":"publisher","DOI":"10.1002\/chem.202303921"},{"key":"e_1_3_3_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.tips.2009.05.005"},{"key":"e_1_3_3_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jalz.2013.06.003"},{"key":"e_1_3_3_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0079-6123(10)83007-9"},{"key":"e_1_3_3_29_2","doi-asserted-by":"publisher","DOI":"10.1006\/nimg.2001.0910"},{"key":"e_1_3_3_30_2","doi-asserted-by":"publisher","DOI":"10.1038\/jcbfm.2008.110"},{"key":"e_1_3_3_31_2","doi-asserted-by":"publisher","DOI":"10.1186\/s40658-015-0132-1"},{"key":"e_1_3_3_32_2","doi-asserted-by":"publisher","DOI":"10.1002\/cpph.9"},{"key":"e_1_3_3_33_2","doi-asserted-by":"publisher","DOI":"10.1016\/B978-0-444-64196-0.00013-3"},{"issue":"1531","key":"e_1_3_3_34_2","first-page":"1","article-title":"Multi-fused S,N-Heterocyclic compounds for targeting \u03b1-Synuclein aggregates","volume":"14","author":"Zheng C","year":"2025","unstructured":"Zheng C, Stehouwer J, Ummenthala GR, et al. Multi-fused S,N-Heterocyclic compounds for targeting \u03b1-Synuclein aggregates. Cells 2025; 14(1531): 1\u201311. doi:https:\/\/doi.org\/10.3390\/cells14191531","journal-title":"Cells"}],"container-title":["Journal of Parkinson\u2019s Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1877718X261431108","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/1877718X261431108","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1877718X261431108","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T07:08:50Z","timestamp":1794640130000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/1877718X261431108"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,17]]},"references-count":33,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["10.1177\/1877718X261431108"],"URL":"https:\/\/doi.org\/10.1177\/1877718x261431108","relation":{},"ISSN":["1877-7171","1877-718X"],"issn-type":[{"value":"1877-7171","type":"print"},{"value":"1877-718X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,17]]}}}